Protalix Biotherapeutics (NYSEAMERICAN:PLX) is set to release its earnings data on Tuesday, March 6th. Analysts expect Protalix Biotherapeutics to post earnings of ($0.06) per share for the quarter.
Shares of Protalix Biotherapeutics (NYSEAMERICAN PLX) traded down $0.01 during trading hours on Tuesday, hitting $0.66. The stock had a trading volume of 313,427 shares, compared to its average volume of 876,162. Protalix Biotherapeutics has a 12 month low of $0.48 and a 12 month high of $1.51. The company has a market capitalization of $326.91, a PE ratio of -0.33 and a beta of 1.02.
Several equities research analysts recently issued reports on the company. Zacks Investment Research cut Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. BidaskClub cut Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Finally, HC Wainwright set a $5.00 price target on Protalix Biotherapeutics and gave the company a “buy” rating in a research note on Thursday, January 4th.
ILLEGAL ACTIVITY NOTICE: This story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3226567/protalix-biotherapeutics-plx-to-release-earnings-on-tuesday.html.
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.